Latest Headlines

Latest Headlines

Microneedle patch targets melanoma cells with anti-PD-1 nanoparticles

In an effort to more effectively target melanoma cells in the skin, researchers at North Carolina State University have developed a microneedle patch embedded with a nanoparticle immunotherapy treatment.

HIV drug increases therapeutic window for skin cancer by slowing drug resistance

Researchers from Cancer Research UK have shown that an HIV drug may be effective in halting skin cancer by preventing its associated drug-resistance--increasing the therapeutic window to reverse cancer progression.

Boston Children's team finds potential new melanoma drug target using zebrafish

Why some cancer-prone cells don't ever cross the line into actually becoming malignant is a mystery that has long eluded scientists. Now, researchers at Boston Children's Hospital have answered that question, at least for melanoma. And in doing so, the team visualized for the first time the spread of cancer from a single cell and identified a set of genes as a potential new drug target.

U.K.'s NICE says yes to Opdivo for advanced skin cancer

Last month the U.K. drug cost watchdog nixed Bristol-Myers Squibb's immunotherapy Opdivo for use against lung cancer, saying in draft guidance that it just cost too much to justify approval. But NICE feels differently when it comes to using Opdivo against skin cancer, today recommending it for approval without even extracting a price cut.

Sanford Burnham team sees promise in new melanoma drug

Scientists at Sanford Burnham Prebys Medical Discovery Institute say that a new molecular machinery-targeting drug dubbed SBI-756 demonstrated preclinical evidence of success in a mouse model for melanoma.

Ready to rumble, Novartis? Roche targets melanoma-fighting combo market with new FDA nod

When Novartis bought GlaxoSmithKline's oncology business, the newest products were a pair of targeted melanoma drugs, Taflinlar and Mekinist. The two meds had racked up trial data showing they beat Roche's own targeted drug Zelboraf when used in tandem.

Daiichi Sankyo and Plexxikon get FDA nod for melanoma combination

Japan's Daiichi Sankyo and its associated company Plexxikon said the U.S. Food and Drug Administration (FDA) has approved cobimetinib for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf (vemurafenib), the company said in a statement.

Novartis' newly acquired melanoma combo wins EU recommendation

Novartis' recently acquired melanoma duo, Tafinlar and Mekinist, has won a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use as a combo treatment for BRAF V600 mutation-positive melanoma

Researchers launch PhI study to test new approach to T cell immunotherapy

In a new wrinkle on the work being done to develop T-cell therapies to fight cancer, a group of investigators in Cleveland say they've seen promising lab results from a new adoptive approach that uses activated T cells extracted from the lymph nodes of melanoma patients.

Merck joins up with NanoString to find genes that predict response to Keytruda

Merck announced that it will deploy NanoString Technologies' nCounter Analysis System as it searches for more genes that predict response to its checkpoint inhibiting cancer drug Keytruda.
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • next ›
  • last »